Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Daiichi, EMD, Exelixis, Gilead, Infinity, Intrabio, Sumitomo, Takeda, Valneva.
BEIJING – Shanghai Junshi Biosciences Ltd. is developing neutralizing antibodies as a potential treatment for COVID-19, and the program will move on to clinical trials soon. Meanwhile, the biotech is set to launch a pre-revenue IPO on Shanghai’s STAR market.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aegea Medical, Biolase, Biofire Defence, Biomérieux, Diacarta, Helius Medical Technologies, Mesa Biotech.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3M, Affinity Health Partners, Allogene Therapeutics, Bellaseno, Curemetrix, Decipher Biosciences, Fiat Chrysler Automobiles, Ford Motor, GE Healthcare, Genmark Diagnostics, Global Center for Medical Innovation, Heat Biologics, Intervenn Biosciences, Iqvia, Letsgetchecked, Maxcyte, Nano-X Imaging, No Borders, Nuclein, Pathsensors, Protex, Q2 Solutions, Qiagen, Quest Diagnostics, Tamarin Health, Vero Biotech, Zoll.